Achaogen to Present at the Stifel 2017 Healthcare Conference
November 06 2017 - 8:01AM
-- Company presentation scheduled for November
14, 2017 at 8:45 a.m. EST --
Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical
company developing innovative antibacterials addressing multi-drug
resistant (MDR) gram-negative infections, today announced that the
Company will be presenting at the Stifel 2017 Healthcare Conference
taking place November 14 to 15, 2017 at the Lotte New York Palace
Hotel. Achaogen management will present at 8:45 a.m. Eastern
Standard Time on Tuesday, November 14th, 2017.
A live audio webcast of the presentation will be available in
the "Investors" section of Achaogen’s website, www.achaogen.com. A
replay of the presentation will be archived for 30 days following
the conference for those unable to listen live.
About AchaogenAchaogen is a late-stage
biopharmaceutical company passionately committed to the discovery,
development, and commercialization of innovative antibacterial
treatments for MDR gram-negative infections. Achaogen is developing
plazomicin, its lead product candidate, for the treatment of
serious bacterial infections due to MDR Enterobacteriaceae,
including carbapenem-resistant Enterobacteriaceae. The Food and
Drug Administration has granted plazomicin Breakthrough Therapy
designation for the treatment of bloodstream infections caused by
certain Enterobacteriaceae in patients who have limited or no
alternative treatment options. The Company's second product
candidate is C-Scape, an orally-administered
beta-lactam/beta-lactamase inhibitor combination. Achaogen's
plazomicin program has been funded, and its C-Scape program is
funded, in part with Federal funds from the Biomedical Advanced
Research and Development Authority. Achaogen has other programs in
early and late preclinical stages focused on other MDR
gram-negative infections and additional disease areas. All product
candidates, including plazomicin, are investigational only and have
not been approved for commercialization. For more information,
please visit www.achaogen.com.
Source: Achaogen, Inc. (NASDAQ: AKAO)
Investor and Media ContactDavid Arrington Vice
President, Investor Relations and Corporate Communications
650.440.5856 darrington@achaogen.com